Navigation Links
Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Date:9/5/2007

New "Oxygen Sandwich" Device is First to Mimic Natural Physical Environment

MIAMI, Sept. 5 /PRNewswire/ -- One of the major challenges to islet cell transplantation as the treatment of choice for type 1 diabetes is the shortage of donor tissue supply. Patients often need a re-infusion of islet cells after the initial treatment, and this means another donor pancreas is needed to provide the fragile islet cells for transplant. New findings by researchers at the Diabetes Research Institute (http://www.diabetesresearch.org) at the University of Miami could represent a big step forward in possibly alleviating the problem.

Up until now investigators have had only moderate success in differentiating either adult stem cells or embryonic stem cells to become insulin-producing beta cells. A large part of the problem has been inducing the proper culture environment in the laboratory. Researchers know that islets require a high amount of oxygen for optimal health, so UM researchers created a new cell culture device called the "oxygen sandwich" to provide the cells with a more natural oxygen environment than those used in traditional culture methods.

"Using mouse pancreatic stem cells, we were able to show that delivering oxygen in a physiological way enhanced enormously their differentiation into beta cells, with insulin levels exceeding 30-fold those observed in control conditions," said Juan Dominguez-Bendala, Ph.D., research assistant professor of surgery, director of the Stem Cell Development and Translational Research Laboratory at the Diabetes Research Institute, and senior author of the study which was published online in Stem Cells Express.

"It is as though these stem cells were just waiting for us to provide them with the conditions they needed to mature. We believe this is a major step toward the efficient generation of beta cells for clinical transplantation."

The new cell culture device, designed by Chris Fraker, senior research associate in the Tissue Engineering Laboratory at the Diabetes Research Institute, closely mimics the natural oxygen environment. The device "sandwiches" the stem cells with oxygen from two sources, one from the top with air diffusing through the culture medium and the second from the bottom with air diffusing through a silicon membrane mixed with perfluorocarbon, a very powerful oxygen reservoir.

"The use of high oxygen to promote differentiation of insulin-producing cells opens the way to many other applications with different sources of progenitor cells, beyond embryonic stem cells and beyond diabetes," said Camillo Ricordi, M.D., scientific director of the Diabetes Research Institute.

About the Diabetes Research Institute

The Diabetes Research Institute is a recognized world leader in cure- focused research. Since its inception in the early 1970s, the DRI has made significant contributions to the field of diabetes research, pioneering many of the techniques used in islet transplantation. From innovations in islet isolation and transplant procedures to advances in cell biology and immunology, the DRI is now harnessing the power of emerging technologies to develop new cell-based therapies to restore insulin production. For the millions of families already affected by diabetes who are looking to the world of science for answers, the Diabetes Research Institute is the best hope for a cure.


'/>"/>
SOURCE Diabetes Research Institute Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD ... Inc. The heightening prevalence of cardiac conditions coupled with the availability of medical ... addition, technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... MB ... a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, ... used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Tranquility acoustic and privacy panel system. , The Tranquility privacy panel system ... a collaborative office environment. Tranquility panels help reduce noise and provide the visual ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family owned ... region, is inaugurating a charity event to honor Chad Phillip Dermyer, a local police ... year, Chad Phillip Dermyer and his fellow officers were conducting routine stops of suspects ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive ... of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer ... each been chosen by their peers for the 2017 list based on their ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a ... the US market. , Over the past 20 years SFI has been recognized as ... has launched six new clients into the US market. The new clients include: ...
Breaking Medicine News(10 mins):